ADC Therapeutics delivered an EPS surprise of +87.50% and a revenue surprise of +20.41% for the quarter ended December 2025. Those sizable beats point to materially stronger-than-expected performance that could trigger analyst estimate upgrades and a share re-rating, though near-term direction depends on company guidance, cash runway and upcoming clinical/regulatory milestones.
ADC Therapeutics delivered an EPS surprise of +87.50% and a revenue surprise of +20.41% for the quarter ended December 2025. Those sizable beats point to materially stronger-than-expected performance that could trigger analyst estimate upgrades and a share re-rating, though near-term direction depends on company guidance, cash runway and upcoming clinical/regulatory milestones.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
